Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Current Leases (2017 - 2025)

KalVista Pharmaceuticals' Current Leases history spans 8 years, with the latest figure at $2.0 million for Q2 2025.

  • On a quarterly basis, Current Leases rose 51.84% to $2.0 million in Q2 2025 year-over-year; TTM through Apr 2025 was $2.0 million, a 51.84% increase, with the full-year FY2025 number at $2.0 million, up 51.84% from a year prior.
  • Current Leases hit $2.0 million in Q2 2025 for KalVista Pharmaceuticals, up from $1.5 million in the prior quarter.
  • Over the last five years, Current Leases for KALV hit a ceiling of $2.0 million in Q2 2025 and a floor of $592000.0 in Q1 2021.
  • Historically, Current Leases has averaged $1.2 million across 4 years, with a median of $1.2 million in 2024.
  • Biggest five-year swings in Current Leases: changed 0.0% in 2021 and later skyrocketed 51.84% in 2025.
  • Tracing KALV's Current Leases over 4 years: stood at $863000.0 in 2021, then soared by 33.02% to $1.1 million in 2023, then rose by 26.48% to $1.5 million in 2024, then surged by 36.16% to $2.0 million in 2025.
  • Business Quant data shows Current Leases for KALV at $2.0 million in Q2 2025, $1.5 million in Q4 2024, and $1.4 million in Q4 2024.